Skip to content
All resources

GLP-1 and metabolic

Glucagon Receptor Agonists Explained: Why Glucagon Is Added to GLP-1 Drugs

AM

By

· 10 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 8 sections
  1. What does glucagon normally do?
  2. What is the evidence that glucagon raises energy expenditure?
  3. Does glucagon act on liver fat directly?
  4. What about blood glucose?
  5. What about heart rate?
  6. Which compounds use glucagon receptor agonism?
  7. What is still unknown?
  8. Frequently asked questions

A glucagon receptor agonist activates the receptor for glucagon, the pancreatic hormone that raises blood glucose. In obesity and liver research it is never used alone: it is combined with GLP-1 receptor agonism in dual agonists such as survodutide, mazdutide and pemvidutide, and with GLP-1 and GIP in the triple agonist retatrutide. The hypotheses are that glucagon adds energy expenditure and acts directly on liver fat. The trade-offs being watched are heart rate and blood glucose. Of these compounds, only mazdutide is approved anywhere, in China.

A liver cell with glycogen granules and a hormone bound to a surface receptor
Illustration in the style of a micrograph, not experimental data: a liver cell, where glucagon receptors are concentrated.

What does glucagon normally do?

Glucagon is made by the alpha cells of the pancreas, and its textbook job is to raise blood glucose between meals by making the liver release and produce glucose. That is why a glucagon agonist looks, at first, like the wrong thing to give someone with obesity or type 2 diabetes.

Glucagon has other actions that drew drug developers to it. In the liver it is linked to fatty acid oxidation and reduced fat synthesis; the pemvidutide investigators describe glucagon agonists as acting directly on the liver to stimulate fatty acid oxidation and inhibit lipogenesis. And glucagon appears to raise energy expenditure. Both actions sound useful for obesity and fatty liver disease, as long as something holds blood glucose down at the same time. That something is GLP-1 agonism.

The three incretin-family receptors are compared in the GLP-1, GIP and glucagon receptor guide. This page is about the glucagon arm specifically.

What is the evidence that glucagon raises energy expenditure?

In people, the evidence is short-term and small. Tan and colleagues ran a randomised, double-blind crossover study in 10 volunteers with overweight or obesity and no diabetes. Each received placebo, GLP-1 alone, glucagon alone, and GLP-1 plus glucagon by infusion. Resting energy expenditure, measured by indirect calorimetry, did not change with GLP-1 alone but rose significantly with glucagon, and rose similarly when glucagon and GLP-1 were given together. Glucagon alone raised plasma glucose; adding GLP-1 rapidly reduced that rise, which the authors attributed to a synergistic effect on insulin secretion. That study is the cleanest human demonstration of the idea, and it lasted hours, not months.

In animals, the evidence is stronger. Boehringer Ingelheim's discovery paper for survodutide reported that, in mice, it reduced body weight more than semaglutide through both lower food intake and higher energy expenditure. Liver gene expression and circulating amino acids were used as markers that the glucagon receptor was being engaged.

Reviewers are cautious about the human picture. A 2026 IUPHAR review by Elmendorf and colleagues on repurposing glucagon states that the mechanisms by which glucagon agonism raises energy expenditure have been evaluated only in preclinical rodent models, and that evidence for similar processes in humans is limited. That is the correct way to hold the energy-expenditure hypothesis: plausible, shown in short human infusions and in rodents, and not yet demonstrated as the reason any long-term trial produced the weight loss it did.

Does glucagon act on liver fat directly?

This is where clinical trials have tested the hypothesis most directly, because liver fat and liver histology can be measured.

Survodutide. In a phase 2 trial in biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis, improvement in MASH without worsening of fibrosis occurred in 43% to 62% of participants across the doses studied, against 14% on placebo. A post hoc mediation analysis by Noureddin and colleagues then asked how much of that effect ran through weight loss. For steatosis measures, most of it did: 58.2% of the effect on MRI liver fat was mediated by weight reduction. For fibrosis improvement, only 36.3% was, and for inflammation and fibrosis blood markers less than half. The authors read this as suggestive of a direct role for glucagon receptor agonism in the liver. A mediation analysis is a statistical decomposition of one trial, not proof of mechanism, but it is the right question to ask.

Pemvidutide. Altimmune's dual agonist was tested in 94 adults with fatty liver disease over 12 weeks. Relative liver-fat reduction reached 68.5% at the best-performing dose level against 4.4% on placebo, while the largest weight change was −4.3%. A liver-fat reduction that large alongside modest weight loss is consistent with a direct hepatic action, though 12 weeks is short. In the phase 2b IMPACT trial in MASH with fibrosis stage F2 or F3, pemvidutide met its endpoint of MASH resolution without fibrosis worsening at 24 weeks (52% to 58% against 20% on placebo) but did not meet its fibrosis-improvement endpoint (33% to 36% against 28%).

Detailed survodutide results are in the survodutide article. Liver fat measured by MRI is a surrogate; what that means for interpreting these results is in surrogate endpoints explained.

What about blood glucose?

The concern is straightforward: glucagon raises glucose. In practice, the dual and triple agonists tested so far have lowered HbA1c in people with type 2 diabetes, because the GLP-1 arm, and in retatrutide's case the GIP arm too, works in the other direction.

The balance shows up in the details. In survodutide's phase 2 diabetes trial, HbA1c fell by 0.91 percentage points at the lowest dose level and by 1.46 to 1.71 at the others, without a clear further gain across the higher levels, while weight continued to fall with dose, to −8.7%. In SYNCHRONIZE-2, survodutide lowered HbA1c by 0.8 to 0.9 points from a baseline of 7.4%, against 0.2 on placebo. In mazdutide's DREAMS-1 trial, HbA1c fell by 1.57 to 2.15 points against 0.14. Whether the glucagon arm limits how far glucose can be pushed down at a given level of GLP-1 activity is exactly the sort of question that a ratio of receptor potencies decides, and it differs between molecules.

What about heart rate?

High doses of exogenous glucagon have acute effects on heart rate, cardiac contraction and blood pressure. A 2026 review by Kushner and Michos looked at what that means for co-agonists. Their conclusions:

  • Clinical studies of GLP-1/glucagon dual agonists, including mazdutide and survodutide, have generally found heart-rate increases similar to those with GLP-1 agonists alone.
  • Mazdutide and survodutide also lowered blood pressure.
  • At least one other dual agonist was discontinued, partly because of unacceptably large heart-rate increases and QT prolongation.
  • Unequivocal evidence that the glucagon receptor is expressed in the human heart is lacking.
  • The differences between compounds may reflect different potencies at the two receptors, so cardiovascular effects need to be established compound by compound.

For retatrutide, the phase 2 obesity trial reported dose-dependent heart-rate increases that peaked at 24 weeks and then declined. That pattern is covered in retatrutide's side effects in trials.

Which compounds use glucagon receptor agonism?

CompoundReceptorsSponsorFurthest stageRegulatory status
MazdutideGLP-1, glucagonInnovent Biologics with Eli LillyPhase 3 publishedApproved in China, 2025, for weight management and type 2 diabetes
SurvodutideGLP-1, glucagonBoehringer IngelheimPhase 3 published in obesity and fatty liver diseaseApproved nowhere
PemvidutideGLP-1, glucagonAltimmunePhase 2b published; phase 3 in MASH recruiting (NCT07795164)Approved nowhere
RetatrutideGIP, GLP-1, glucagonEli LillyPhase 3 published in 2026Approved nowhere

Each has its own receptor balance. "GLP-1/glucagon dual agonist" describes a design, not a single pharmacology, which is why survodutide, mazdutide and pemvidutide should not be treated as interchangeable. The individual programmes are in the mazdutide and survodutide articles, and retatrutide's in retatrutide and the triple agonist idea and its TRIUMPH phase 3 trials. Approaches that pair GLP-1 with something other than glucagon, such as amycretin and MariTide, are compared in the 2026 incretin pipeline overview.

What is still unknown?

Whether the glucagon arm adds anything to weight loss in people over the long term, beyond what an equally potent GLP-1 or GLP-1/GIP agonist would do, has not been tested head to head. This article found no published trial comparing a glucagon co-agonist with an otherwise matched molecule lacking glucagon activity. Cardiovascular outcome trials, notably survodutide's SYNCHRONIZE-CVOT, have not published. And the liver findings rest on histology and imaging over 24 to 48 weeks; outcome trials in cirrhosis and advanced fibrosis are still running.

Supplied here for laboratory use: Retatrutide. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.

Research-chemical retatrutide is not Lilly's investigational product, and none of the trial results above describe it. Nothing here is medical, dosing, or therapeutic guidance.

Frequently asked questions

Why would a weight-loss drug activate the glucagon receptor if glucagon raises blood sugar? Because glucagon also appears to raise energy expenditure and to act on liver fat, and pairing it with GLP-1 agonism holds glucose down. In a human infusion study, glucagon raised resting energy expenditure and blood glucose, and adding GLP-1 rapidly reduced the glucose rise. Long-term trials have shown net HbA1c reductions.

Do glucagon receptor agonists raise heart rate? A 2026 review concluded that GLP-1/glucagon dual agonists such as survodutide and mazdutide have generally raised heart rate to a similar extent as GLP-1 agonists alone, while lowering blood pressure. At least one other dual agonist was discontinued partly because of large heart-rate increases. Effects differ between compounds.

Is the energy-expenditure effect proven in people? No. It has been shown in short human infusion studies and in rodents. A 2026 IUPHAR review states that mechanistic data come from preclinical rodent models and human evidence is limited. No long-term trial has shown that higher energy expenditure explains the weight loss seen with these drugs.

Which glucagon co-agonists are approved? Mazdutide is approved in China for weight management and type 2 diabetes. Survodutide, pemvidutide and retatrutide are approved nowhere, though survodutide and retatrutide have published phase 3 results and pemvidutide has a phase 3 MASH trial recruiting.

Selected Research References

  1. Tan TM, Field BC, McCullough KA, et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes. 2013;62:1131-1138. pubmed.ncbi.nlm.nih.gov/23248172
  2. Zimmermann T, Thomas L, Baader-Pagler T, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Molecular Metabolism. 2022;66:101633. pubmed.ncbi.nlm.nih.gov/36356832
  3. Elmendorf AJ, Yousefian M, Kim IM, et al. IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes. Pharmacological Research. 2026;223:108077. pubmed.ncbi.nlm.nih.gov/41478576
  4. Noureddin M, Sanyal AJ, Bedossa P, et al. Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH. Hepatology. 2026. pubmed.ncbi.nlm.nih.gov/42545725
  5. Harrison SA, Browne SK, Suschak JJ, et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. Journal of Hepatology. 2025;82:7-17. pubmed.ncbi.nlm.nih.gov/39002641
  6. Noureddin M, Harrison SA, Loomba R, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. The Lancet. 2025;406:2644-2655. pubmed.ncbi.nlm.nih.gov/41237796
  7. Blüher M, Rosenstock J, Hoefler J, et al. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia. 2024;67:470-482. pubmed.ncbi.nlm.nih.gov/38095657
  8. Kushner PR, Michos ED. Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus. Journal of the American Heart Association. 2026;15:e049727. pubmed.ncbi.nlm.nih.gov/42535526
  9. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389:514-526. pubmed.ncbi.nlm.nih.gov/37366315

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.